Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 100,004 shares at $12.30 ($1.2M) on 2025-04-07, disclosed to the SEC on 2025-04-08.
Scheduled sale ($1.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.30 | 50,002 | $615K | 50.0% |
| 2 | $12.30 | 50,002 | $615K | 50.0% |
| Total | $12.30 avg | 100,004 | $1.2M | 100% |
| Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |
| SPRY | SELL | 2023-09-05 | $771K | — | Filing → |